Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -24782.35% is 100% above its 3-year average of -9086211288054272.00%, near the high end of its 3-year range (-54517267728253976.00%–-3779.07%).
46.04% below its 12-month average of -16969.96%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -14792.86%.
EBITDA MARGIN
-24782.35%
EBITDA MARGIN AVG TTM
-16969.96%
EBITDA MARGIN AVG 3Y
-10903453545664372.00%
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-46.04%
CURRENT VS 3Y AVG
+100.00%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
PRF Technologies Ltd.
Market Cap
$71110.00
EBITDA Margin
-24782.35%
TTM Avg
-16969.96%
3Y Avg
-10903453545664372.00%
5Y Avg
N/A
Market Cap
$61495.00
EBITDA Margin
-1762.94%
TTM Avg
-1134.94%
3Y Avg
-792.43%
5Y Avg
-12891.91%
Market Cap
$108729.00
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$31083.00
EBITDA Margin
-51.60%
TTM Avg
-25.53%
3Y Avg
-32.59%
5Y Avg
-16.80%
Market Cap
$30509.00
EBITDA Margin
-44.11%
TTM Avg
-77.20%
3Y Avg
-45.21%
5Y Avg
-40.80%
Market Cap
$6115.00
EBITDA Margin
-216.38%
TTM Avg
-116.97%
3Y Avg
-54.20%
5Y Avg
-40.74%
Market Cap
$242924.00
EBITDA Margin
-994.74%
TTM Avg
-759.01%
3Y Avg
-558.46%
5Y Avg
-556.54%
Market Cap
$380715.00
EBITDA Margin
-47981.26%
TTM Avg
-69951.07%
3Y Avg
-52738.28%
5Y Avg
-42190.63%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| PRF Technologies Ltd. (PRFX) | $71110.00 | -24782.35% | -16969.96% | -10903453545664372.00% | N/A |
| Akanda Corp. (AKAN)vs › | $61495.00 | -1762.94% | -1134.94% | -792.43% | -12891.91% |
| Psyence Biomedical Ltd. (PBM)vs › | $97282.00 | N/A | N/A | N/A | N/A |
| Silexion Therapeutics Ltd. (SLXN)vs › | $108729.00 | N/A | N/A | N/A | N/A |
| Zhongchao Inc. (ZCMD)vs › | $31083.00 | -51.60% | -25.53% | -32.59% | -16.80% |
| Mobile-health Network Solutions Class A Ordinary Shares (MNDR)vs › | $30509.00 | -44.11% | -77.20% | -45.21% | -40.80% |
| NewGenIvf Group Limited (NIVF)vs › | $6115.00 | -216.38% | -116.97% | -54.20% | -40.74% |
| SciSparc Ltd. (SPRC)vs › | $242924.00 | -994.74% | -759.01% | -558.46% | -556.54% |
| Virax Biolabs Group Limited (VRAX)vs › | $380715.00 | -47981.26% | -69951.07% | -52738.28% | -42190.63% |
| Niki BioSolutions, Inc. (NIKI)vs › | $381940.00 | -2196.68% | -1727.24% | -1664.72% | -2055.32% |
Gross Margin
-4864.7%
EBITDA Margin
-24782.3%
Operating Margin
-29335.3%
Net Margin
-22521.5%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -14792.86% |
| 2026-03-31 | -14792.86% |
| 2025-12-31 | -25576.47% |
| 2025-09-30 | -12717.65% |
| 2024-03-31 | -54517267728253976.00% |
| 2022-12-31 | -3779.07% |
